Skip to main content

FDA 21 CFR Part 11 & E-Signature Compliance Guides

Expert guides on FDA 21 CFR Part 11, ALCOA+ data integrity, GxP compliance, and electronic signature requirements for clinical trials, pharma, and life sciences.

Regulatory ComplianceLatest

21 CFR Part 11 Electronic Signature Validation: IQ OQ PQ Step-by-Step Guide

A practical guide to IQ, OQ, and PQ validation for 21 CFR Part 11 e-signature systems, including CSA's risk-based approach, specific test cases for each Part 11 control, and what FDA investigators look for.

April 27, 202612 min read

All Articles

Clinical Trials

Electronic Signatures for CROs: What Contract Research Organizations Need for Part 11 Compliance

CROs are explicitly named as regulated entities in the October 2024 FDA guidance, with Part 11 obligations enforceable through the sponsor-CRO written agreement. This guide covers the non-repudiation letter requirement, dual-site accountability, TMF e-signature requirements for CRO monitoring workflows, delegation of authority log management across multi-site environments, and system qualification responsibility.

April 20, 202612 min read
Clinical Trials

Clinical Trial Document Management: E-Signature Requirements for Sites and Sponsors

Managing clinical trial documents with e-signatures requires a framework that satisfies FDA 21 CFR Part 11, ICH E6(R3), and the October 2024 FDA final guidance. This guide covers the documents sites and sponsors must sign, delegation of authority log requirements, TMF retention obligations, and platform evaluation criteria.

April 13, 202613 min read
Buyer's Guide

What Makes an E-Signature Platform FDA Compliant? The Complete Technical Checklist

Every e-signature vendor claims FDA compliance. This guide explains what Part 11 Subpart B and Subpart C actually require at the technical level — hash-chained audit trails, authentication at signing, signature meaning, tamper-evident records, and validation documentation — plus a 14-question checklist to run against any vendor.

April 10, 202615 min read
Regulatory Compliance

E-Signatures for Pharmaceutical QA: Batch Records, SOPs, and Deviation Reports

Pharmaceutical QA signatures on batch records, SOPs, deviations, and CAPA reports must meet FDA 21 CFR Part 11 and Part 211 requirements. This guide covers GMP-specific signature obligations including reason-for-change, batch record audit trail review, SOP routing enforcement, and the critical differences between general e-signature tools and purpose-built GMP platforms.

April 10, 202614 min read
Regulatory Compliance

GxP Electronic Signature Requirements: What GMP, GLP, and GCP Each Demand

GMP, GLP, and GCP all require FDA 21 CFR Part 11 compliance for electronic signatures, but each discipline adds specific obligations on top of the shared foundation. This guide compares what each GxP discipline requires — from GCP non-repudiation letters and delegation of authority logs to GLP study director designations and GMP per-batch audit trail reviews.

April 7, 202614 min read
Regulatory Compliance

21 CFR Part 11 Compliant Electronic Records: Subpart B Requirements Explained

Subpart B of FDA 21 CFR Part 11 defines the requirements for compliant electronic records, covering validation, audit trails, access controls, record retention, and signature-to-record linking. This guide explains each section of Subpart B, common FDA 483 failures, and what the 2024 clinical investigations guidance changed for cloud-based systems.

April 6, 202612 min read
Regulatory Compliance

FDA Inspection Readiness: Audit Trail Requirements and the Pre-Inspection Checklist

What does an FDA investigator actually request when reviewing electronic signature audit trails? This guide covers exactly what investigators ask for, the 5 most common 483 audit trail findings, and a pre-inspection checklist you can run against your system today.

April 4, 202613 min read
Buyer's Guide

Choosing the Best E-Signature for Clinical Trials: 8 Requirements

What makes an e-signature platform right for clinical trials? This guide covers the 8 specific requirements drawn from 21 CFR Part 11, the FDA's 2024 final guidance, ICH E6(R3), and EU CTR 536/2014 — including guest signing, delegation of authority logs, IQ/OQ validation docs, and 25-year retention.

March 30, 202611 min read
Regulatory Compliance

Electronic Signature Audit Trail Requirements: 21 CFR Part 11, Annex 11, and ALCOA+

What does FDA actually require for electronic signature audit trails? This guide covers the specific requirements under 21 CFR Part 11 Section 11.10(e), EU GMP Annex 11 Clause 9, and ALCOA+ — including what inspectors look for and the most common audit trail failures in FDA 483 observations.

March 30, 202612 min read
Regulatory Compliance

ALCOA+ Audit Trail Software: What Life Sciences Teams Should Require

What does ALCOA+ compliant audit trail software actually need to do? This guide covers the 8 core technical requirements, common FDA 483 findings, and the specific questions to ask any vendor before purchase.

March 27, 202611 min read
Buyer's Guide

Best 21 CFR Part 11 Compliant E-Signature Software (2026): What Actually Matters

Most vendors claim Part 11 compliance. Few can back it up technically. This guide covers the 7 requirements that separate genuinely compliant e-signature platforms from those that just claim it, plus the questions to ask during vendor evaluation.

March 27, 202612 min read
Regulatory Compliance

Part 11 Electronic Signatures: Requirements, Components, and Common Mistakes

A practical guide to 21 CFR Part 11 electronic signature requirements -- Subpart B and Subpart C explained, common compliance failures at clinical research sites, and what FDA inspectors look for in 2026.

March 23, 20269 min read
Data Privacy

Electronic Signatures and GDPR Compliance: Full Guide

E-signature workflows process personal data (names, emails, IPs) subject to GDPR. This guide covers lawful bases under Article 6, data minimization, DPA requirements, cross-border transfers, data subject rights, retention policies, and a 12-point compliance checklist.

March 16, 20269 min read
Regulatory Compliance

FDA Warning Letters Are Up 73%. Is Your Audit Trail Ready?

FDA warning letters jumped 73% in H2 2025. Here's what clinical trial sponsors and CROs need to know about Part 11 audit trails before your next inspection.

March 16, 20268 min read
Regulatory Compliance

ALCOA+ Data Integrity: 9 Principles for Life Sciences

ALCOA+ stands for Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available. This guide explains each principle with GxP examples, common FDA 483 violations, and practical implementation strategies for electronic records.

March 14, 202610 min read
Regulatory Compliance

Audit Trails in Regulated Industries: Complete Guide

An audit trail is a secure, computer-generated record of who did what, when, and why in a regulated system. This guide covers FDA 21 CFR Part 11 Section 11.10(e), EU GMP Annex 11, hash chain verification, common 483 findings, and implementation best practices.

March 13, 202610 min read
Clinical Trials

EU Clinical Trial Regulation 536/2014: Sponsor Guide

EU CTR 536/2014 replaced the Clinical Trials Directive with a harmonized framework featuring the CTIS portal, single application process, and mandatory 25-year retention under Article 58. This guide covers documentation, timelines, transparency, and e-signature requirements.

March 12, 202611 min read
Buyer's Guide

DocuSign Part 11 Module vs Purpose-Built Compliance Platforms

DocuSign addresses FDA 21 CFR Part 11 through a paid add-on module. Purpose-built platforms embed compliance controls natively. This guide compares the two architectures across audit trails, 2FA, validation burden, total cost of ownership, and organizational fit for life sciences.

March 11, 202611 min read
Buyer's Guide

How to Validate an E-Signature System: IQ/OQ/PQ Under CSA

Learn how to validate an e-signature system using IQ/OQ/PQ under FDA's 2025 Computer Software Assurance (CSA) guidance. Covers risk-based testing, Part 11 mapping, qualification checklists, change control, and common validation pitfalls for pharma, biotech, and medical device companies.

March 11, 202612 min read
Buyer's Guide

E-Signature Vendor Evaluation Checklist: RFP Questions for Regulated Life Sciences

40+ RFP questions for evaluating e-signature vendors in pharma, biotech, and CROs. Covers FDA 21 CFR Part 11, EU GMP Annex 11, and ALCOA+ data integrity requirements with a weighted scoring template.

March 11, 202616 min read
Regulatory Compliance

FDA Warning Letters & Data Integrity: Lessons from Real Enforcement Actions

Data integrity deficiencies appear in 60-80% of FDA drug GMP warning letters. This guide examines real warning letters citing shared logins, missing audit trails, backdated records, and absent training — with consequences including consent decrees, import bans, and criminal prosecution.

March 11, 202613 min read
Clinical Trials

Decentralized Clinical Trials & eConsent: E-Signature Requirements

Decentralized clinical trials (DCTs) use telehealth and direct-to-patient technologies for remote trial conduct. This guide covers the FDA's September 2024 DCT guidance, eConsent best practices, e-signature compliance under Part 11 and ICH E6(R3), and data integrity for remote workflows.

March 11, 202611 min read
Buyer's Guide

How to Migrate to a Part 11 E-Signature Platform: 6-Phase Framework

Migrating from paper or legacy systems to a 21 CFR Part 11 compliant e-signature platform requires structured change control. This guide covers a six-phase migration framework: requirements, validation, pilot, parallel running, cutover, and decommission — with audit trail continuity and training strategies.

March 11, 202612 min read
Regulatory Compliance

Medical Device E-Signatures Under QMSR, ISO 13485 & EU MDR

The FDA's QMSR replaced the QSR on February 2, 2026, incorporating ISO 13485:2016 by reference. This guide covers how e-signatures interact with the new QMSR, Part 11's independent requirements, EU MDR documentation obligations, and validation strategies for dual-market medical device companies.

March 11, 202613 min read
Regulatory Compliance

AI & Electronic Signatures in Regulated Industries: Compliance Guide

AI is transforming e-signature workflows in life sciences — from intelligent document routing to anomaly detection and predictive compliance. This guide covers the FDA's AI guidance, EU AI Act high-risk classification, Part 11 implications, and a risk-based framework for adopting AI-enhanced compliance tools.

March 11, 202613 min read
Buyer's Guide

CSV vs CSA: Computer System Validation vs Software Assurance Explained

FDA's Computer Software Assurance (CSA) guidance, finalized September 2025, replaces traditional CSV with risk-based validation. This guide compares CSV and CSA approaches, explains risk classification for e-signature functions, and provides practical transition strategies for life sciences organizations.

March 11, 202613 min read
Regulatory Compliance

EU GMP Annex 11 (2025 Draft): Computerized Systems Compliance Guide

The 2025 draft revision of EU GMP Annex 11 expands from 5 to 19 pages, adding provisions for AI, cybersecurity, cloud/SaaS, and enhanced e-signature requirements including multi-factor authentication and eIDAS alignment. This guide covers key changes, FDA Part 11 comparison, and preparation strategies.

March 11, 202613 min read
Buyer's Guide

How to Choose an E-Signature Platform for Life Sciences

Evaluating e-signature platforms for pharma, biotech, and medical devices? This guide covers FDA 21 CFR Part 11 compliance, audit trail capabilities, 2FA requirements, validation documentation, red flags to avoid, and total cost of ownership for regulated industries.

March 10, 202611 min read
Healthcare

HIPAA-Compliant Electronic Signatures: Requirements Guide

HIPAA allows electronic signatures but requires BAAs, encryption (AES-256), audit controls, and MFA for documents containing PHI. This guide covers Security Rule safeguards, BAA requirements, audit trails, and best practices for healthcare organizations.

March 6, 20269 min read
Regulatory Compliance

eIDAS vs ESIGN Act: Complete Comparison Guide (2026)

The EU eIDAS Regulation defines three signature tiers (SES, AES, QES) while the US ESIGN Act is technology-neutral with a single tier. This guide compares legal frameworks, cross-border recognition, eIDAS 2.0 changes, and compliance strategies for multinational organizations.

March 3, 20269 min read
Regulatory Compliance

GxP Compliance for Electronic Records: GLP, GMP, GCP Guide

GxP compliance requires electronic records to be attributable, immutable, and audit-trailed. This guide covers GLP, GMP, GCP, GDP, and GVP requirements, ALCOA+ principles, EU Annex 11, system validation (IQ/OQ/PQ), and best practices for life sciences.

February 28, 202610 min read
Clinical Trials

Electronic Signatures in Clinical Trials: 2024 FDA Guidance Update

The FDA finalized 29 Q&As on electronic systems in clinical investigations in October 2024, resolving ambiguities around non-repudiation letters, hybrid records, cloud platforms, and risk-based validation. This guide explains what changed and what it means for sponsors, CROs, and research sites.

February 25, 202614 min read
Regulatory Compliance

FDA 21 CFR Part 11: Complete Compliance Guide (2026)

FDA 21 CFR Part 11 defines requirements for electronic records and electronic signatures in FDA-regulated industries. This guide covers all three subparts, audit trail requirements, common 483 findings, and a compliance checklist for pharma, biotech, and medical devices.

February 21, 202612 min read
Fundamentals

Digital Signatures vs Electronic Signatures: Key Differences

Digital signatures use PKI cryptography to verify identity and detect tampering. Electronic signatures are broader, covering any electronic intent to sign. Learn when to use each in regulated industries like pharma and healthcare.

February 18, 20268 min read
Fundamentals

What Are Electronic Signatures? Definition, Types & Legal Validity

Electronic signatures (e-signatures) are legally binding electronic indications of intent to sign a record. Learn how they work, their legal validity under ESIGN and eIDAS, the three types (SES, AES, QES), and why regulated industries need compliant solutions.

February 15, 202610 min read

Ready for Compliant E-Signatures?

Start your free trial and see how Certivo meets compliance requirements for your regulated industry.

Start Free TrialView Compliance